News and Analysis | Published:

Alzheimer amyloid hypothesis lives on

Nature Reviews Drug Discovery volume 16, pages 35 (2017) | Download Citation

Despite the failure of Eli Lilly's anti-amyloid antibody solanezumab in its latest phase III trial for Alzheimer disease, a bulging pipeline of amyloid-modulating candidates and novel clinical trial strategies still hold promise.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2016.281

Authors

  1. Search for Asher Mullard in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing